Suppr超能文献

美国实体器官移植受者中的霍奇金淋巴瘤。

Hodgkin lymphoma among US solid organ transplant recipients.

机构信息

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20892, USA.

出版信息

Transplantation. 2010 Nov 15;90(9):1011-5. doi: 10.1097/TP.0b013e3181f5c3a6.

Abstract

BACKGROUND

To assess the risk and identify risk factors of Hodgkin lymphoma (HL) in solid organ transplant recipients. Prior research has been limited by the rarity of HL and the requirement for extended follow-up after transplantation.

METHODS

Using data from the Scientific Registry of Transplant Recipients (SRTR), we conducted a retrospective cohort study of US solid organ transplant recipients (1997-2007). We estimated hazard ratios (HRs) for HL risk factors using proportional hazards regression. Standardized incidence ratios (SIRs) compared HL risk in the transplant cohort with the general population.

RESULTS

The cohort included 283,190 transplant recipients (average follow-up: 3.7 years after transplantation). Based on 73 cases, HL risk factors included male gender (HR: 2.1, 95% CI: 1.2-3.7), young age (4.0, 2.3-6.8), and Epstein-Barr virus (EBV) seronegativity at the time of transplantation (3.1, 1.2-8.1). Among tumors with EBV status information, 79% were EBV positive, including all tumors in recipients who were initially seronegative. Overall, HL risk was higher than in the general population (SIR: 2.2) and increased monotonically over time after transplantation (SIR: 4.1 at 8-10 years posttransplant). Excess HL risk was especially high after heart and/or lung transplantation (SIR: 3.2).

CONCLUSION

HL is a late complication of solid organ transplantation. The high HL risk in recipients who were young or EBV seronegative at the time of transplant and the fact that most HL tumors were EBV positive highlight the role of primary EBV infection and poor immune control of this virus. The occurrence of HL may rise with improved long-term survival in transplant recipients.

摘要

背景

评估实体器官移植受者罹患霍奇金淋巴瘤(HL)的风险并识别相关风险因素。既往研究受到 HL 的罕见性以及移植后需进行长期随访的限制。

方法

我们利用美国器官移植受者科学注册处(SRTR)的数据,开展了一项 US 实体器官移植受者(1997-2007 年)的回顾性队列研究。我们使用比例风险回归估计 HL 风险因素的风险比(HR)。标准化发病比(SIR)用于比较移植队列与普通人群的 HL 风险。

结果

该队列纳入了 283190 名移植受者(移植后平均随访时间:3.7 年)。根据 73 例病例,HL 的风险因素包括男性(HR:2.1,95%CI:1.2-3.7)、年轻(4.0,2.3-6.8)和移植时 EBV 阴性(HR:3.1,1.2-8.1)。在具有 EBV 状态信息的肿瘤中,79%为 EBV 阳性,包括所有最初 EBV 阴性的受者的肿瘤。总体而言,HL 风险高于普通人群(SIR:2.2),并且在移植后随时间推移呈单调递增(移植后 8-10 年 SIR:4.1)。心脏和/或肺移植后 HL 风险尤其高(SIR:3.2)。

结论

HL 是实体器官移植的晚期并发症。在移植时年轻或 EBV 阴性的受者中 HL 风险较高,且大多数 HL 肿瘤为 EBV 阳性,这突出了原发性 EBV 感染和对该病毒的免疫控制不佳的作用。随着移植受者的长期生存改善,HL 的发生可能会增加。

相似文献

5
Plasma cell neoplasms in US solid organ transplant recipients.美国实体器官移植受者中的浆细胞肿瘤。
Am J Transplant. 2013 Jun;13(6):1523-32. doi: 10.1111/ajt.12234. Epub 2013 May 1.

引用本文的文献

1
Malignancy: An Adverse Effect of Immunosuppression.恶性肿瘤:免疫抑制的不良反应。
Handb Exp Pharmacol. 2022;272:315-335. doi: 10.1007/164_2021_554.

本文引用的文献

4
Epstein-barr virus and hodgkin lymphoma.爱泼斯坦-巴尔病毒与霍奇金淋巴瘤
Hematology Am Soc Hematol Educ Program. 2007:204-9. doi: 10.1182/asheducation-2007.1.204.
8
Cancer incidence before and after kidney transplantation.肾移植前后的癌症发病率。
JAMA. 2006 Dec 20;296(23):2823-31. doi: 10.1001/jama.296.23.2823.
9
Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS.霍奇金淋巴瘤与艾滋病毒/艾滋病患者的免疫缺陷
Blood. 2006 Dec 1;108(12):3786-91. doi: 10.1182/blood-2006-05-024109. Epub 2006 Aug 17.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验